Market Closed -
Nasdaq
04:00:00 2024-05-10 pm EDT
|
5-day change
|
1st Jan Change
|
8.74
USD
|
-0.68%
|
|
-10.36%
|
+59.49%
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
799.9
|
526.1
|
846.9
|
-
|
-
|
Enterprise Value (EV)
1 |
525.5
|
526.1
|
705.5
|
702.6
|
623
|
P/E ratio
|
-9.8
x
|
-9.61
x
|
-14.3
x
|
-25.5
x
|
22.1
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
608
x
|
17,535
x
|
153
x
|
9.91
x
|
4
x
|
EV / Revenue
|
399
x
|
17,535
x
|
127
x
|
8.22
x
|
2.94
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
93,770
|
95,997
|
96,894
|
-
|
-
|
Reference price
2 |
8.530
|
5.480
|
8.740
|
8.740
|
8.740
|
Announcement Date
|
3/23/23
|
3/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
1.316
|
0.03
|
5.543
|
85.45
|
211.9
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-35.52
|
-67.52
|
-64.94
|
-27.41
|
67.76
|
Operating Margin
|
-
|
-2,698.78%
|
-225,066.67%
|
-1,171.6%
|
-32.08%
|
31.97%
|
Earnings before Tax (EBT)
1 |
-
|
-34.68
|
-54.36
|
-55.37
|
-20.85
|
79.52
|
Net income
1 |
-20.24
|
-34.68
|
-54.36
|
-59.23
|
-35.04
|
39.96
|
Net margin
|
-
|
-2,635.41%
|
-181,216.67%
|
-1,068.61%
|
-41%
|
18.86%
|
EPS
2 |
-0.8300
|
-0.8700
|
-0.5700
|
-0.6100
|
-0.3433
|
0.3950
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/6/22
|
3/23/23
|
3/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
0.02
|
0.01
|
-
|
-
|
-
|
-
|
1
|
4.34
|
2.8
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-15.44
|
-18.71
|
-20.6
|
-17.98
|
-57.29
|
-13.19
|
-11.15
|
-18.84
|
-24.73
|
-
|
Operating Margin
|
-
|
-93,565%
|
-206,030%
|
-
|
-
|
-
|
-
|
-1,883.6%
|
-569.84%
|
-
|
Earnings before Tax (EBT)
1 |
-14.43
|
-14.96
|
-17.37
|
-14.87
|
-7.168
|
-10.29
|
-8.475
|
-16.69
|
-22.72
|
-
|
Net income
1 |
-14.43
|
-14.96
|
-17.37
|
-14.87
|
-7.168
|
-10.29
|
-12.54
|
-16.19
|
-20.06
|
-
|
Net margin
|
-
|
-74,805%
|
-173,700%
|
-
|
-
|
-
|
-
|
-1,619.3%
|
-462.2%
|
-
|
EPS
2 |
-0.0900
|
-0.1600
|
-0.1800
|
-0.1600
|
-0.0700
|
-0.1100
|
-0.1300
|
-0.1650
|
-0.2050
|
-0.1900
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/23/23
|
5/15/23
|
8/10/23
|
11/9/23
|
3/21/24
|
5/9/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
274
|
-
|
141
|
144
|
224
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
0.2
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
15.12%
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/6/22
|
3/23/23
|
3/21/24
|
-
|
-
|
-
|
Last Close Price
8.74
USD Average target price
19
USD Spread / Average Target +117.39% Consensus |
1st Jan change
|
Capi.
|
---|
| +59.49% | 847M | | +17.96% | 44.96B | | +48.77% | 41.85B | | +1.17% | 42.65B | | -4.27% | 29.04B | | +11.42% | 26.08B | | -21.39% | 19.03B | | +4.86% | 12.75B | | +27.29% | 12.06B | | -3.50% | 11.75B |
Other Biotechnology & Medical Research
|